Tag Archive for: Mestag Therapeutics

Weekly Roundup: Enrolment completed and conference top tips and takeaways

Gesynta Pharma completes enrolment in Phase 2 NOVA trial evaluating vipoglanstat in endometriosis Gesynta Pharma AB, a clinical-stage biotech company developing vipoglanstat, a non-hormonal, non-opioid therapy that could transform the standard of care for women with endometriosis, announced that it has completed enrolment in NOVA, its Phase 2 clinical proof-of-concept and dose-finding trial. A total […]

Mestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors

— Mr. Astley-Sparke brings more than two decades of biotech leadership, having scaled several highly innovative transatlantic companies, including Replimune, uniQure and BioVex — Dr. Sandor brings more than 20 years of oncology clinical development experience, including leading programs to regulatory approval at Array BioPharma, Incyte and AstraZeneca — Appointments strengthen the Board as Mestag evaluates […]

Weekly Roundup: Exciting clinical stage updates and your LSX Nordic Congress summary

Progress for our clients in the clinic this week, with Mestag Therapeutics dosing the first patient in their STARLYS clinical trial and STORM Therapeutics to present data on its dose escalation study at ASCO later this month. More good news, as Hansa Biopharma entered a multi-million-Euro licensing agreement with SERB S.A. Bring on the bank […]

Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial

 — STARLYS trial to evaluate the potential of MST-0312, a targeted lymphotoxin-beta (LTBR) agonist bispecific antibody, as a novel therapeutic strategy for the treatment of solid tumors. — Study to evaluate tertiary lymphoid structure (TLS) and high endothelial venule (HEV) formation in the tumor as well as clinical responses, as monotherapy and in combination with […]

Weekly roundup: Rising leaders and growing momentum

Drum roll… In Vivo’s 2026 Rising Leaders were announced this week and included not one, not two, but five Optimum clients. A huge congratulations to Colleen Acosta of Freya Biosciences, Diana Čekatauskaitė of Lonza’s Synaffix, Reuben Dawkins of Link Biologics, Michelle Morrow of Nucleome Therapeutics, and Javier Nunez-Vicandi of Sofinnova Partners. This list recognises not […]

© Optimum Strategic Communications.